Streetbeat News

Stock Prices

DRIO

DarioHealth presented two new studies at the ADA Scientific Sessions, showing that 31% of Dario members with Type 2 diabetes achieved remission using the Dario digital platform over 12 months. The research also included members tracking GLP-1 medication.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:31 pm

SFTBF

SFTBY

SoftBank CEO Masayoshi Son has seen a significant drop in shareholder support for his reappointment, falling from 95.93% to 79.22% in a year, following a recommendation by proxy advisor ISS. The decline is attributed to SoftBank's average return on equity of less than 5% over the past five years. Activist investor Elliott Investment Management has also demanded a $15 billion share buyback. Despite these challenges, SoftBank's stock has surged nearly 50% this year, driven by the rally of Arm Holdings Plc.

Portfolio Pulse from Benzinga Neuro

June 25, 2024 | 12:21 pm

PILBF

PMETF

Volatility in lithium pricing in China is attracting retail investors to mining companies, according to Patriot Battery Metals CEO Ken Brinsden. The Chinese market's sensitivity to price over quality fosters spot market transactions, increasing volatility. This benefits day traders but complicates capital costs for producers. South Korean and Japanese buyers prefer long-term contracts, offering more stability. Patriot Battery Metals is developing a significant lithium property in Quebec.

Portfolio Pulse from Matt Whittaker

June 25, 2024 | 12:20 pm

BYDDY

TM

BYD Co Ltd has launched its third electric vehicle model, the BYD Seal sedan, in Japan, directly competing with Toyota's RAV4 PHEV. The Seal will be available in two variants, with deliveries starting in July and August. BYD is offering an introductory discount for the first 1,000 customers.

Portfolio Pulse from Anan Ashraf

June 25, 2024 | 12:18 pm

HUMA

Humacyte, Inc. (NASDAQ:HUMA) presented positive preclinical data for its BioVascular Pancreas (BVP) program, a potential treatment for type 1 diabetes. The BVP product candidate showed promising results in restoring normal blood glucose levels in diabetic mice and demonstrated islet survival and continued insulin production in non-human primate models.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:14 pm

BALL

CHRW

CRDO

MQ

NET

Top Wall Street analysts have upgraded their ratings for several companies, including Marqeta, C.H. Robinson Worldwide, Ball Corporation, Cloudflare, and Credo Technology Group. These upgrades reflect positive outlooks and increased price targets for the respective stocks.

Portfolio Pulse from Avi Kapoor

June 25, 2024 | 12:13 pm

MNPR

Monopar Therapeutics Inc. (NASDAQ:MNPR) announced that its abstract on the evaluation of an anti-uPAR antibody as a radiopharmaceutical for imaging and treatment of solid tumors has been accepted as a 'Top-Rated Oral Presentation' at the EANM 2024 Annual Congress.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:12 pm

BIVI

BioVie Inc. presented the protocol design for its upcoming SUNRISE-PD Phase 2 trial of bezisterim (NE3107) in early Parkinson's disease patients at the ATMRD 2024 Congress. The trial will evaluate the drug's effect on motor and non-motor symptoms in approximately 60 patients. Data from an earlier Phase 2a trial were also highlighted.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:11 pm

ALLR

Allarity Therapeutics announced that multiple patients in its Phase 2 Stenoparib trial have exceeded 30 weeks on treatment, indicating positive progress in the trial.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:10 pm

LFMD

LifeMD, Inc. (NASDAQ:LFMD) has launched private health insurance acceptance for its virtual primary care services, including weight management. Initially available in select states, the company plans to expand coverage nationwide and begin accepting Medicare by early 2025.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:10 pm